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Abstract 
Most of our knowledge regarding glioma cell biology comes from cell culture experiments. 
For many years the standards for glioma cell culture were the use of cell lines cultured in the 
presence of serum and 20% O2. However, in vivo, normoxia in many brain areas is in close to 
3% O2. Hence, in cell culture, the experimental value referred as the norm is hyperoxic 
compared to any brain physiological value. Likewise, cells in vivo are not usually exposed to 
serum, and low-passaged glioma neurosphere cultures maintained in serum-free medium is 
emerging as a new standard. A consequence of changing the experimental normoxic 
standard from 20% O2 to the more brain physiological value of 3% O2, is that a 3% O2 
normoxic reference point enabled a more rigorous characterization of the level of regulation 
of genes by hypoxia. Among the glioma hypoxia-regulated genes characterized using this 
approach we found VE-cadherin that is required for blood vessel formation, and Filamin B a 
gene involved in endothelial cell motility. Both VE-Cadherin and Filamin B were found 
expressed in pseudopalisades, a glioblastoma pathognomonic structure made of hypoxic 
migrating cancer cells. These results provide additional clues on the role played by hypoxia in 
the acquisition of endothelial traits by glioma cells and on the functional links existing 
between pseudopalisades, hypoxia, and tumor progression.  
 
key words: glioma; hypoxia; pseudopalisade; VE-cadherin, Filamin B; endothelial to 
mesenchymal transition. 
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Introduction. 
Since the establishment of the HeLa cell line [1], cancer cell culture has been linked with 
cancer research progress. Most of our current knowledge regarding cancer cell biology 
comes from data issued from cancer cell cultures. Even in vivo experiments, such as tumor 
xenograft, have extensively used cancer cells which have been amplified in culture in the 
presence of serum and under 20% O2. Possible drawbacks in the use of these growth 
conditions are linked to the facts that i) cells in vivo are not usually challenged by serum 
components [2], ii) 20% O2 is a far higher oxygen concentration than the physiological levels 
experienced by cells in vivo [3-6]. For example, normoxic pO2 for rat brain tissue is in the 
range of 19-40 mm Hg (≈2.6 – 5.6% O2) in the grey cortex,  6-16 mm Hg (≈0.8 – 2.2% O2) in 
the white matter, 11-16 mm Hg (≈1.5 – 2.2% O2) in the hypothalamus, and 20-33 mm Hg 
(≈2.8 – 4.6% O2) in the hippocampus [3]. 
The situation becomes increasingly complex for pathologic tissues such as brain tumors. It 
has long been known that most tumors outgrow their oxygen supply and/or have leaky 
vessels that are inefficient in oxygen delivery. Therefore, brain tumors, like other solid 
tumors, exhibit chronic or periodic hypoxic areas. These points are critical since tumor 
hypoxia has been associated with tumor propagation, malignant progression and resistance 
to therapy [4]. Hence characterizing the response of glioma cells to hypoxia is a highly 
relevant field of investigation. This in turn needs defining what a normoxia value is. If pO2 
around 1% O2 or below are usually considered as hypoxic, several different values of pO2 
ranging from 20% (cell culture “normoxia”) to 6%-1% (tissue normoxia) can be used to define 
experimental brain cell normoxia [5-8]. The problem of the choice of the standard conditions 
for cell culture is critical.  
In this study, we used two different experimental cell models to determine the 
transcriptional response of glioma cells to hypoxia (0.3% O2) and normoxia conditions. The 
first one is the U87 glioma cell line (ATCC HTB-14) which has been established and routinely 
cultured in normoxia conditions (20% O2) in the presence of serum. This cell line has been 
considered as a standard glioma cell line for many years (more than 1000 references in 
PubMed using U87 and glioma as keywords). However, culturing glioma cells from freshly 
resected tumor as neurospheres and in serum-free medium, usually referred as glioma stem 
cell cultures, is now considered as a more reliable standard for investigating glioma cell 
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biology [2]. Therefore experiments were also performed on low-passaged glioma 
neurosphere cultures constantly maintained in serum-free medium and under physiological 
brain normoxia (3% O2) conditions [5].  
This study aimed at the characterization of relevant hypoxia-inducible genes in glioma cells 
using new standard conditions of normoxia.  The results obtained provide new insights of 
how hypoxia can induce the expression of endothelial genes in glioma cell culture and in 
pseudopalisades, a glioblastoma morphological hallmark that links vascular pathology, 
hypoxia, cancer cell migration and tumor vessel formation [9].  
 
Material and Methods. 
The study was approved by the Biological Resource Center Ethics Review Board 38043 
Hospital of Grenoble. Written consent was obtained from each patient or family. 
 
Cell culture: Glioma cells used were the U87 MG glioma cell line (ATCC: HTB14) and two 
glioma neurosphere cultures (Glio5 and Glio6) established from freshly dissociated surgical 
specimen as previously described [5]. U87 cells were grown as a monolayer in DMEM 
supplemented with 10% fetal calf serum under standard atmospheric conditions (20% O2). 
Glio5 and Glio6 cultures were maintained under neurospheres at 3% O2 in serum- free 
medium (DMEM/F12) supplemented with 0.5 N2, 0.5 B27, 30 ng/ml bFGF and 30 ng/ml EGF, 
and 0.0002% heparin. These cells have the capacity for self-renewal, express CD133 and are 
tumorigenic when orthotopically implanted in nude mice [5] (Supplementary Material Fig.1). 
For experiments with adherent U87 cells, flasks were incubated stationary for 4 hours after 
seeding to allow cell attachment, then, they were placed for 48 hours on a PS-3D Rotator 
(Grant-Bio) adjusted to 10 rotations per minute with a platform inclined angle of 7°. This 
gentle shaking avoided the formation of pO2 gradients observed when monolayer cells are 
cultured in a stagnant medium. Cells were at 50% confluency at the end of the experiment. 
Glio6 were grown as floating sphere in serum-free medium. To minimize oxygen gradients in 
spheroids, cells were seeded at low density so that the sphere size at the end of the 
experiment had a diameter of less than 100 µm. For hypoxic conditions, cell cultures were 
maintained in an InVivo2 ™ hypoxic workstation under a gas mixture of 0.3% O2. Cell 
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cultures under gas mixture of 3% O2 were incubated in a Sanyo MCO-5M multi-gas 
incubator.  
 
In vitro migration assay: 
For the in vitro down-regulation of FLNB, we used the validated FLNB-siRNA SI02653175 
from Qiagen (Qiagen, France) which targets the ACGCATTGACATCCAGATGAA FLNB 
sequence. Control siRNA was the Negative Control siRNA (cat. no. 1022076) provided by 
Qiagen. Transfection was performed using the Lipofectamine® RNAiMAX reagent 
(InVitroGen, France) according to the manufacturer’s instructions. For migration studies, 
Boyden’s chambers (Becton Dickinson Biosciences, France) with 8-µm pore size polyethylene 
terephthalate membrane were used according to the manufacturer’s instructions. Briefly, 
U87 glioma cells were transfected with FLNB siRNA or control siRNA at a final concentration 
of 10 nM. 72 hours later, transfected cells were harvested and resuspended in DMEM 
medium with 1% FCS. 2 x 10
4 
were seeded onto the upper compartment of each chamber 
and placed into wells containing 700µl of DMEM medium with 10% FCS. The migration 
chambers were incubated 6h at 37°C in hypoxic conditions (0.3% O2). Following incubation, 
the inserts were fixed in 4% paraformaldehyde (PAF) and stained with Hoescht (Sigma 
Aldrich, France). Quantitation of migrating cells on the lower surface of each membrane was 
done by counting ten random fields under a fluorescence microscope. Each assay was 
performed in triplicate. The data from three independent experiments were pooled for 
statistical analysis. 
 
Gene expression profiling:  
Total RNAs were extracted from cells with the MirVana isolation kit™ (Ambion, Applied 
Biosystems, Foster City, CA) and further controlled (Bio-Analyser, Agilent Technologies, Palo 
Alto, CA) for quality and concentration. 200 ng of total RNA were amplified with the 
GeneChip 3’IVT Express Kit  (Affymetrix, Santa Clara, CA) and then hybridized on GeneChip 
Human Genome U133 Plus 2.0 according to Affymetrix specifications. The expression values 
of the samples, reported in arbitrary units, were processed and normalized using RMA 
algorithm. A minimum of three independent analyses using independent cell cultures were 
performed for each cell line (Glio 6 and U 87) and for each condition of O2 (20%, 3%, 0.3%). 
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The expression changes between two conditions of O2 were validated with the statistical t- 
test with a p ≤ 0.05 considered as significant. The regulated genes showing significant ratio 
(i.e., mRNA expression under the lower oxygen level divided by mRNA under the higher 
oxygen level) less or equal to 0.55 or more or equal to 1.80 were listed.  All array data sets 
are available at GEO under accession number GSE32100 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=dlkpvsogeqqgkly&acc=GSE32100 
 
RT-qPCR: 2 µg of total RNA were transcribed into cDNA using Promega Reverse Transcription 
reagents with random dN6 primers. PCR primers for each gene were designed using the Universal 
ProbeLibrary Assay Design Center (https://www.roche-applied-
science.com/sis/rtpcr/upl/ezhome.html) and sequences are given as supplementary table IV. 
Then real-time PCR were performed according to the SYBR Green methodology on an 
Mx3000
TM
 apparatus (Stratagene, La Jolla, CA). The normalization of the results was realized 
with ACTB, whose expression is not affected by pO2 according to our Affymetrix data. 
Finally, the statistical validation of gene changes was checked with the statistical  t-test.  
Tissue samples and immunohistochemistry:  
FLNB immunohistochemistry: Two non-tumoral brain tissues and forteen glioblastomas were 
studied. Tissue samples were taken at surgery for pharmacoresistant epilepsy (control 
tissue) and for brain tumors respectively. For histological classification, tumor samples were 
fixed in formalin and the diagnoses were made on paraffin-embedded material using the 
current World Health Organization classification of tumors of the central nervous system 
criteria. FLNB immunostaining was carried out on formalin-fixed and paraffin-embedded 
tissue sections using the Ventana Benchmark Autostainer (Ventana Medical International 
Inc., Illkirch, France). 4 µm cut sections were boiled for 90 min in citrate buffer for heat-
induced epitope retrieval. The primary antibody (rabbit polyclonal ref HPA004747, SIGMA,  
USA) was applied at a 1:200 dilution for 2 h. Slides incubation with normal rabbit IgG at the 
same concentration as the primary antibody were used as negative controls.  
VE-Cadherin immunohistochemistry was performed on 10 another glioblastomas also 
diagnosed according the WHO classification. After deparaffinization, 4µm thick sections 
were boiled for 90 min in citrate buffer for heat-induced epitope retrieval. The primary 
antibody (rabbit polyclonal ref HPA030562, SIGMA, USA) was applied at room temperature 
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at a dilution of 1:300. Detection was performed using HRP EnVision
TM
 following the 
manufacturer protocol (DAKO, France). 
 
Results. 
- U87 cells:  20% vs 0.3% O2. 
In a first set of experiments, we determined the response of U87 glioma cells to hypoxia. The 
cell response to hypoxia is usually studied by shifting cell cultures from normoxia (20% O2) 
to less than 1% O2. Accordingly, our transcriptomic analyses were first performed using cell 
cultures maintained either under atmospheric oxygen or shifted to 0.3% O2 for 48 hours. 
Using the criteria for selection defined in the material and methods section (variation fold 
≤0.55 or ≥1.80; p ≤ 0.05), 265 different genes were found deregulated by hypoxia in glioma 
U87 cells (218 up-regulated, 47 down-regulated; Supplementary Material Table I, and Fig. 1, 
set A).  However, as previously discussed [5-8], the use of 20% O2 as a normoxic reference is 
debatable. This value is much higher than the oxygen values experienced by brain cells in 
vivo. Therefore, when the O2 level was decreased from 20% O2 to 0.3% O2 (hypoxia) it is 
critical to distinguish which part of the observed variations in gene expression is due to 
hypoxia and which part is due to the withdrawal of experimentally-imposed hyperoxic 
conditions. To investigate this we analyzed the transcriptomic response of U87 cells when 
the cultures were shifted from culture normoxia (20% O2) to the median brain pO2 
normoxia value (3% O2). 
 
- U87 cells: 20% vs 3% O2. 
At least 29 genes can be found differentially regulated (variation fold ≤0.55 and ≥1.80; 
p≤0.05) when the U87 cells were shifted from 20% to 3% O2. All of these genes were 
identified as differentially expressed between 20% and 0.3% O2 (p≤ 0.05) (Table I). However, 
the fold-variation of the expression levels of these genes was generally two times lower at 
3% compared to 0.3% O2. These results demonstrated that at least several genes already 
described as hypoxia-regulated can be better considered as oxygen-sensitive, since their 
expression was significantly increased or decreased at 3% O2 which corresponds to the brain 
median normoxic level. Consequently, using 20% O2 as a normoxic standard leads to 
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overestimate the variation fold of some genes, since significant changes in gene expression 
can already occur between 20% and 3% O2. This fact can be evidenced by calculating the 
ratio between the variation folds obtained at 20 vs 0.3% O2 and the variation folds between 
20% and 3% O2 (Table I; calculated hypoxic variation fold).  Consequently, in some cases, 
qualifying a gene as hypoxia-inducible may depend both on the normoxic reference and on 
the threshold values for significant variations used. 
- Glio6 cells: 3% vs 0.3% O2 
As an alternative to the use of the ATCC U87 glioma cell line, which is routinely cultured in 
serum-containing medium and under 20% O2, we used a glioma stem cell culture (Glio6) 
derived from a freshly resected tumor that has been established and consistently cultured as 
floating spheres in serum-free medium and under 3% O2 [5]. Defining 3% O2 as a normoxic 
reference point and serum-free medium for cancer cell culture has the advantage to 
preserve CD133 expression [5]. In addition, this new normoxic standard was a way to avoid 
the overestimation in gene expression variation folds evidenced above for the U87 cell line. 
For a transfer of 3% to 0.3% O2 for 48 hours, 87 genes were found differentially expressed in 
the Glio6 cells (same cut off parameters as described above; Supplementary Material Table  
II, and Fig. 1, set B).  
 
- Glio6 cells: 3% vs 0.3% O2 in the presence of serum. 
As stated above the Glio6 cells were cultured in serum-free medium, which is the standard 
culture condition for cancer stem cells. Accordingly, it is commonly assumed that in vivo 
glioma cells are not naturally exposed to serum and that culturing these cells in the presence 
of serum may be a source of artifacts
 
[2].  However, intravascular thrombosis and 
microscopic tumoral hemorrhages are frequently observed in glioma [10,11]. This may cause 
some glioma cells to be exposed to serum during the course of the disease. A notable point 
in the context of this study is that since the presence of serum reflects the existence of 
abnormal or injured vessels, glioma cells challenged with serum components in vivo could 
also experience low oxygen tensions. Therefore, in the glioma microenvironment, serum and 
hypoxia can be two concomitant stimuli involved in glioma progression. Therefore, we 
challenged Glio6 cells to a hypoxic shift (3% to 0.3% O2) in the presence of 10% fetal calf 
serum for 48 hours, and identified 103 differentially expressed genes. (Fig. 1 set C; 
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Supplementary Material Table III). Interestingly we identified IGFBP3 as a gene whose 
induction by hypoxia is serum dependent (Fig. 2 A, B) 
 
Identification of a non-exhaustive core set of hypoxia-regulated genes in glioma 
cells. 
A cross-analysis between the data obtained with U87 and Glio6 showed that the intersection 
of set A (U87 20% vs 0.3% O2, with serum), set B (Glio6 3% vs 0.3% O2, without serum), and 
set C (Glio6 3% vs 0.3% O2, with serum) gave a list of 32 genes regulated by hypoxia both in 
Glio6 cells cultured with or without serum and U87 cells cultured with serum (Fig. 1 and 
Table II). This set can be considered as a non-exhaustive core set of genes regulated by 
hypoxia in glioma cells. It includes numerous genes that are well known to be regulated by 
hypoxia (CA9, VEGF, ENO2… ). Three of these genes (HK2, SLC16A3 and TXNIP) are regulated 
independently by hypoxia and by serum.  Five genes code for unidentified proteins or 
proteins with unknown function and present new potential areas of research. They 
correspond to the GenBank entries W57613.1, AL110176, AA543084 (Affymetrix probe set: 
236180_at; 232451_at; 236480_at), to the hypothetical locus LOC100506211 (probe set: 
230710_at)  and to WDR5B (probe set: 235850).  
 
Identification of novel hypoxia-inducible genes associated to the vascular 
endothelial phenotype conversion of glioma cells. 
Recent data point to the differentiation of glioblastoma cells into vascular endothelial cells 
as a crucial process for tumor survival [12-16]. Hypoxia is suggested to be involved in tumor 
stem cell differentiation into endothelial cells [12]. Importantly, the U87 cell line, although 
tumorigenic, is unable to generate endothelial phenotypes
 
[13]. Therefore, it can be 
expected that some genes critical for the acquisition of endothelial traits should be 
expressed in Glio6 cells and not in U87 cells. Therefore, we looked after genes that were up-
regulated by hypoxia in Glio6 cells, but whose expression was not or poorly detectable in 
U87 cells even under hypoxia. We found only three genes fulfilling these criteria (Fig. 3A). 
These genes code for the Vascular Endothelial Cadherin (VE-Cad alias CDH5 or CD144), the 
Vascular Endothelial Protein Tyrosine Phosphatase (VE-PTP or PTPRB), and CD133 (Fig. 3A). 
VE-cad and VE-PTP are vascular endothelial cell markers. They are necessary for endothelial 
cell-cell junction formation. CD133 which is usually considered as a cancer stem cell marker, 
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is also expressed by vascular endothelial progenitor cells. RT-qPCR analyses performed for 
CD133, VE-Cad, VE-PTP on Glio6 and on Glio 5 (another low-passaged glioma cell culture) 
confirmed the data obtained by hybridization to the Affymetrix chips (Fig. 3B and 
Supplementary Material: Fig. 2). A notable finding of RT-qPCR analyses was that the levels of 
induction by hypoxia of CD133 and VE-PTP were significantly lower in the presence of serum 
(Fig. 3B).  
We then looked after the genes regulated by hypoxia in Glio6 that are constitutively 
expressed in U87 cells. Using our cut-off values, we found filamin B (flnb) as a gene up-
regulated by hypoxia in Glio 6 in the presence and absence of serum and which was 
expressed at high levels in U87 even under 20% O2 (Fig. 4A). RT-qPCR analyses performed 
for flnb on Glio6 and Glio5 confirmed the up-regulation of flnB by hypoxia and its expression 
at high levels in U87 cells (Fig 4B). However, it is noticeable that the Affymetrix array signal 
values obtained with U87 cells for flnb in hypoxia indicated a 1.3 fold (p<0.05) increase in 
comparison to the expression level under normoxia. Nevertheless, this ratio was lower than 
the threshold of significance (≥1.80) we defined for screening our transcriptomic data. 
 
Detection of VE-Cadherin and Filamin B in pseudopalisading cells and functional 
role of Filamin B in glioma cell migration. 
In endothelial cells VE-Cad is involved in several functions including cell-cell adhesion, 
intracellular signaling and transcriptional regulation [17]. These multiple functions prompted 
us to investigate the distribution of VE-Cad in patient samples. In addition to endothelial 
cells of brain blood capillaries (Fig. 5B), an intense VE-Cad immunostaining was detected in 
pseudopalisading cells which correspond to hypoxic tumor cells surrounding necrotic foci 
(Fig. 5A).  For FLNB similar results were found (Fig. 5C,D). As FLNB is known to be involved in 
endothelial cell motility [18], and since pseudopalisades are made by actively migrating 
tumor cells moving away from necrotic hypoxic foci [9,19,20], we investigated the possible 
function of FLNB in glioma cell motility by transfecting cells with siRNA against Filamin B. We 
observed a decreased migration of glioma cells treated with an siRNA-FLNB compared to 
cells transfected with control si-RNA (Fig. 4C).   
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Discussion. 
In tumor tissues such as brain cancer, hypoxia is commonly viewed as a driving force in 
glioma progression. Therefore, identifying the gene expression modifications of glioma cells 
in response to hypoxia is a relevant field of investigation. However, in this kind of 
experiments, the value used to define the experimental normoxia is critical. At the organ 
level, brain normoxia is highly heterogeneous and varies depending on the anatomical 
structures from 0.8% O2 to 6% O2
 
[3]. Consequently, in normal brain, oxygen is a micro-
environmental variable just as, for example, the extra-cellular matrix. This point is critical not 
only for cell culture conditions but also for glioma cell plasticity. Since glioma cells are highly 
invasive, they will experience a wide range of pO2 not only in the tumor mass but also when 
they invade brain parenchyma. To what extend this physiological brain heteroxia influences 
tumor progression is a point that remains to be investigated.  
Our data provide additional clues on the consequences of using the 20% atmospheric oxygen 
level as a normoxic standard in experiments dedicated to study the glioma cell response to 
hypoxia. This overestimates the gene expression variation fold for genes which are already 
regulated between 20% and 3% O2. This finding is consistent with the observation that the 
binding activity of the transcription factor HIF that plays a central role in oxygen homeostasis 
[21] exponentially increases in cell cultures between 20% and 0.5% O2 [22]. One non 
exclusive mechanism for this fine regulation occurring between 20% and 3% O2 could 
involve HIFs posttranslational modifications. For example hydroxylation of HIF by two 
different kinds of hydroxylases (PHDs and FIH) with different affinities for oxygen is a 
possible way to achieve the goal of regulating both HIF stability (PHD) and transcriptional 
activity (FIH) in the tissue normoxic range (6%-1% O2) [23,24]. Our analysis was restricted on 
the transcriptomic response at only one time point (48 hours) and provides a non-exhaustive 
list of genes regulated between 20% and 3% O2 in the U87 glioma cell line. Further studies 
investigating the consequences of a 20% to 3% O2 shift at shorter or longer time points on 
the transcriptome and on the phosphorylation status of proteins are necessary for a better 
understanding of the consequences of culturing glioma cells at 20% O2. The epigenetic 
status of glioma cells is also probably modified by long time culture at 20% O2. According to 
that is the finding that the long term in vitro expansion of human glioblastoma cells at 20% 
O2 instead of 3% O2 irreversibly alters in vivo aggressiveness and AC133 expression [25].  
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The use of a physiological normoxic conditions at 3% O2 for brain-derived cell cultures is a 
mean to circumvent the problem raised by hyperoxic cell culture conditions. Not only it 
provides a pO2 relevant to the median brain normoxic value, but it also allows a more 
rigorous characterization of the effects of hypoxia on gene regulation. We found a set of 32 
genes that are commonly regulated under 0.3% either in U87 (20 vs 0.3% O2) and Glio6 cells 
(3% vs 0.3% O2, with and without serum) (Fig. 1). This set of genes can be considered as a 
non exhaustive core set of genes regulated by hypoxia in glioma cells. An analysis of this list 
of genes in GEOprofile with the keyword hypoxia (http://www.ncbi.nlm.nih.gov/geoprofiles) 
showed that all these genes have previously been described as hypoxia-regulated either in 
glioma cells or in other experimental models. Hence, these results validate our experimental 
approach and analyses. Accordingly, when these 32 significantly differentially expressed 
genes were uploaded into DAVID for functional annotation clustering, overexpressed GO 
groups were “glucose metabolic process”, “response to hypoxia” and “response to organic 
substance”.   
 
hypoxia-induced expression of vascular endothelial genes in glioma cells. 
Recent data have provided evidence that in glioblastoma, a set of endothelial cells in the 
tumor vessels can derive from the tumor cells themselves [12,13,16]. In comparison to 
glioma stem cell cultures established from freshly dissociated surgical specimen, the U87 cell 
line is unable to generate endothelial phenotypes [13]. Hypoxia is suggested to be involved 
in tumor cell differentiation into endothelial cells [12]. Therefore, it can be expected that 
some genes critical for the acquisition of endothelial phenotype are expressed in Glio6 cells 
and regulated by hypoxia, but poorly expressed in U87 cells either at 20% or 0.3% O2. We 
found three genes regulated in common by hypoxia in the presence and absence of serum in 
Glio6 which are not detected as expressed in our transcriptomic analyses in U87 cells (Fig 3). 
They code for the vascular endothelial cadherin (VE-Cad or CDH5), the vascular endothelial 
tyrosine phosphatase (PTPRB) and CD133. According to their names VE-Cad (CDH5) and VE-
PTP (PTPRB) are vascular endothelial cells proteins. VE-Cad is an endothelial cell-cell 
adhesion protein that plays critical roles in endothelial cell biology. It is required for 
maturation, extension and remodeling of vessels [17]. In addition to these properties, VE-
cadherin is a signaling molecule interacting with β-catenin and modulating activity of growth 
factor receptors such as VEGF-R2 and TGFβ receptors [17]. Our finding that VE-Cad is 
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expressed in pseudopalisading cells (Fig. 5), which are known to be in a hypoxic 
microenvironment, suggests several possible functions for this protein both in the 
acquisition of endothelial-like features by cancer cells and in cancer progression. The 
expression of the second identified gene, VE-PTP, has been until now restricted to 
endothelial cells [17]. It is a phosphatase associated with VE-Cad which enhances VE-Cad 
mediated cell-cell adhesion [17]. Like VE-Cad, VE-PTP is required for blood vessel 
development [26,27].  VE-PTP interacts with VE-cadherin to facilitate endothelial cell 
contacts [28]. Silencing of VE-PTP expression in endothelial cells reduces the adhesive 
function of VE-Cad and enhances cell proliferation through activation of Tie-2 [29]. It also 
regulates the spreading and migration of endothelial cells during angiogenesis [30]. Hence, 
our data provide additional clues on how hypoxia could be associated with the acquisition of 
an endothelial phenotype by cancer cells and in the formation of mosaic vessels. Regarding 
CD133, it is usually considered by neuro-oncologists as a brain tumour stem cell marker 
through its epitope AC133. However, CD133 is also a marker of endothelial progenitor cell 
[31]. The CD133+ brain cancer stem-cell is a subpopulation of cancer cells with endothelial 
progenitor features [16]. The fact that CD133 is expressed in the glioblastoma cell 
population which differentiates into endothelial cells and that this process is crucial for 
tumor survival [13] is consistent with the use of CD133 as a cancer stem cell marker. Our 
finding that serum down-regulates the hypoxia-induced CD133 expression could provide an 
explanation for the existence of CD133
-
 cancer cells.  Indeed, a consequence of intravascular 
thrombosis and microscopic tumoral hemorrhages which are frequently observed in glioma 
[10,11] is the presence of serum in a hypoxic tumor micro-environment. Thus, this presence 
of serum could decrease CD133 gene expression. We also found that serum participates to 
the up-regulation of IGFBP3 by hypoxia (Fig. 2). Therefore, our data provides clues for a 
synergic role of serum and hypoxia in cancer progression since IGFBP3 promotes TGFβ-
mediated cell mesenchymal transition [32]. In this regard it is noteworthy that TGFβ is 
increased in the plasma of patients with glioblastoma [33]. This led to suggest the existence 
of an additional model of glioma progression involving a process named endothelial to 
mesenchymal progression [34].  
On the other hand, the use of low passaged glioma cells maintained in serum-free medium 
under 3% O2 allowed us to characterize FLNB as a new hypoxia-inducible gene.  This gene 
was found hypoxia-inducible in Glio6 and Glio 5, and constitutively highly expressed in U87 
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cells (Fig 4, and Supplementary Material: Fig. 2). Like VE-Cad, FLNB is required for the 
development of vascular network [35].  Immunodetection of FLNB in tumor samples (Fig. 5), 
revealed for the first time its overexpression at the level of pseudopalisading cells. 
Pseudopalisading cells are considered as glioma cells migrating away from hypoxic/anoxic 
foci [19]. FLNB is known to regulate the initiation of cell migration and plays also a key role in 
endothelial cell motility and vascular development [18,30,36]. Accordingly we found that 
FLNB knock-down decreases glioma cell migration in vitro (Fig. 4C). This suggests that FLNB 
could participate to pseudopalisading cell migration in vivo. The evaluation of the potential 
of FLNB as a possible therapeutic target in the control of glioma cell invasion from 
hypoxic/perinecrotic pseudoplisading areas warrants further studies.  
In conclusion, we have shown the interest of determining 3% O2 as the normoxic point value 
for quantifying the transcriptomic response of glioma cells to hypoxia. Using this normoxic 
value we have been able to characterize a new set of hypoxia-inducible genes which include 
VE-Cad and FLNB. In addition, we demonstrated the localization of the corresponding 
proteins in pseudopalisading structures. This provides further evidence to consider 
pseudopalisade not only as a cellular architecture useful for glioblastoma diagnosis but also 
as a functional driver for glioblastoma tumor progression linking hypoxia, cancer cell 
migration and tumor vessel formation [9].   
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Figures Legends.  
 
Table I: Hypoxia regulated genes versus oxygen sensitive genes. A non-exhaustive list of 
genes regulated (≥ 1,80 or ≤ 0,55; p ≤ 0.05) in U87 cells both under hypoxia 20% O2 vs 0.3% 
O2, and following return to normoxia (20% O2 vs 3% O2). 
 
 
Table II: A non-exhaustive core set of genes regulated by hypoxia in glioma cells. 
List of the 32 differentially expressed genes associated with hypoxia  (≥ 1,80 or ≤ 0,55 and 
p≤0.05) in both U87 cells (20% vs 0.3% O2) and Glio6 (3% vs 0.3% O2) in the presence and 
absence of serum. 
 
 
Fig. 1: The glioma cell core response to hypoxia. 
Venn diagrams showing the number of genes differentially regulated in U87 cells cultured in 
0.3% O2 when 20% O2 is used as the normoxic reference, and the number of genes 
differentially regulated in Glio6 cells cultured either in the absence or in presence of serum 
(FCS: Fetal calf serum) in 0.3% when 3% O2 is used as the normoxic reference (cf table II).  
 
 
Fig.2: IGFBP3, a gene up-regulated by hypoxia in the presence of serum. 
20 
 
RNA were extracted from Glio6 cells cultured in normoxia (Glio6: 3% O2) or hypoxia (0.3% 
O2) for 48 hours. Glio6 cells were cultured either in the presence or absence of serum. RNA 
were then processed for transcriptomic analyses (abbreviation used FCS: fetal calf serum).  
A: Expression levels are expressed as arbitrary units corresponding to the hybridization 
signal values on Affymetrix Genechips. * p≤ 0.05. 
B: RT-qPCR analysis was performed with primers specific for IGFBP3. Data were normalized 
to  β-actin  * p≤ 0.05 
 
 
Fig.3: VE-cad, VE-PTP and CD133, three genes up-regulated by hypoxia in Glio6 cells, but 
whose expression is poorly detectable in U87 cells even under hypoxia.  
RNAs were extracted from cells cultured in normoxia (U87: 20% O2; Glio6: 3% O2) or hypoxia 
(0.3% O2) for 48 hours. Glio6 cells were cultured either in the presence or absence of serum. 
RNAs were then processed for transcriptomic analyses. 
 A: Expression levels are expressed as arbitrary units corresponding to the hybridization 
signal values obtained with Affymetrix arrays. * p≤ 0.05; ** p≤ 0.01; # values below 
background. 
 
B: RT-qPCR analysis was performed with primers specific for VE-cad, VE-PTP, CD133. 
Expression levels were normalized relative to the expression level of β-actin. Values are 
calculated by 2
-(Ctgene of interest-Ctbetaactin)
  * p≤ 0.05; ** p≤0.01.  
 
 
Fig. 4:  Filamin B: Regulation of FLNB expression by hypoxia in cultured glioma cells and 
effect of FLNB siRNA on cell migration.  
Trancriptomic analyses were performed on RNAs extracted from cells cultured in normoxia 
(U87: 20% O2; Glio6: 3% O2) or hypoxia (0.3% O2) for 48 hours. Glio6 cells were cultured in 
the presence or absence of serum.  
A: RNAs were processed for analyses by hybridization on Affymetrix chips. Expression levels 
of FLNB gene are expressed as arbitrary units corresponding to the hybridization signal 
values. Hybridization signals below 60 are considered as non detected; * p≤ 0.05. 
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B: RT-qPCR analysis was performed with primers specific for FLNB. Expression levels of the 
FLNB gene were normalized relative to the expression level of  β-actin. Values are calculated 
by 2
-(CtFLNB-Ctbetacatin)
;
 
* p≤ 0.05. 
C: FLNB modulates glioma cell migration in vitro.  Filamin B siRNA significantly reduces 
glioma cell migration in Boyden’s chamber assays; ** p≤ 0.01 (n = 3). 
 
Fig. 5: VE-Cadherin and FLNB are expressed in cancer pseudopalisading cells. 
An intense VE-Cadherin (A, B) and FLNB (C, D) staining was detected in pseudopalisading 
guarland-like structure (*) (A, C), and in blood capillaries (black arrow) (B, D) (Magnification 
folds: A = 100X, C= 40X, B= 160X et D=80X). 
 
Supplementary Materials. 
 
Fig.1: Glio5 and Glio6 cells grow as neurospheres, express CD133 and are tumorigenic. 
(A,D):  Nonadherent neurospheres of Glio5 (A) and Glio6 (D) growing in serum-free medium 
at 3% O2  (Magnification fold: 100X).  
(B,E):  Flow cytometric analysis for CD133 expression of Glio5 (B) and Glio6 (E) cells cultured 
under 3%O2. CD133 (AC133, green); non-speciﬁc negative isotypic control IgG1 antibody is in 
black.  
(C,F):  Orthotopic xenograft assay. 50000 Glio5 cells (C) or Glio6 cells (F) were implanted by 
stereotactic injection into the right striatum of SCID mice. The Kaplan-Meier method was 
used to plot animal survival. Animal care was carried out in line with relevant European 
Community regulations (Official Journal of European Community L358 12/18/1986). 
 
 
Fig. 2: FLNB, VE-cad, VE-PTP and CD133, are up-regulated by hypoxia in Glio5. 
RNAs were extracted from glioma stem cell cultures constantly maintained under normoxia 
(3% O2) or exposed to hypoxia (0.3% O2) for 48 hours. Glio5 cells were cultured as 
neurospheres in serum-free medium. RT-qPCR analysis was performed with primers specific 
for FLNB, VE-cad, VE-PTP, and CD133. Expression levels were normalized relative to the 
expression level of β-actin. Values are calculated by 2
-(Ctgene of interest-Ctbetaactin)
 ; * p≤ 0.05. 
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Table I: Genes differentially regulated in U87 glioma when cells are shifted from 20% to 
0.3% O2. 
 
Table II: Genes differentially regulated in Glio6 cells cultured in serum-free medium when 
cultures are shifted from 3% to 0.3% O2. 
 
Table III: Genes differentially regulated in Glio6 cells cultured in the presence of 10% fetal 
calf serum when cultures are shifted from 3% O2 to 0.3% O2. 
 
Table IV. Sequences of primers used for RT-qPCR analyses. 
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Figure 3A 
 
0
0,005
0,01
0,015
0,02
0,025
*
*
E
x
p
re
ss
io
n
 v
a
lu
e
s 
(A
U
)
CD133
20% O2
3% O2
0.3% O2
VE-Cad
E
x
p
re
ss
io
n
 v
a
lu
e
s 
(A
U
)
VE-PTP
E
x
p
re
ss
io
n
 v
a
lu
e
s 
(A
U
)
*
U87 Glio6 Glio6  FCS U87 Glio 6 + FCSGlio6
U87 Glio6 Glio6 FCS
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1
*
*
0
0,002
0,004
0,006
0,008
0,01
0,012
*
*
Glio6 FCS
*
 
Figure 3B 
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Probe Set ID 
Gene 
Symbol 
3% vs 20% O2 
ratio 
0.3% vs 20% O2 
ratio 
Calculated  hypoxic variation fold 
(0.3 vs 20% O2)/(3% vs 20% O2) 
210095_s_at IGFBP3 3.9 7.71 1.98 
237335_at ZP1 3.14 8.27 2.63 
219888_at SPAG4 2.94 7.21 2.45 
236180_at --- 2.77 3.87 1.40 
205832_at CPA4 2.73 5.2 1.90 
218149_s_at ZNF395 2.55 5.6 2.20 
232693_s_at 
FBXO16 /// 
ZNF395 2.48 5.4 2.18 
236480_at --- 2.36 4.17 1.77 
225342_at AK3L1 2.35 4.5 1.91 
201250_s_at SLC2A1 2.32 5.69 2.45 
219410_at TMEM45A 2.29 5.03 2.20 
221748_s_at TNS1 2.29 4.27 1.86 
202887_s_at DDIT4 2.29 3.99 1.74 
201010_s_at TXNIP 2.12 2.77 1.31 
206686_at PDK1 2.06 2.75 1.33 
228843_at --- 2.06 4.33 2.10 
202022_at ALDOC 2.06 4.53 2.20 
215446_s_at LOX 2.03 4.26 2.10 
236915_at C4orf47 2.02 5.49 2.72 
204508_s_at CA12 1.95 3.49 1.79 
230372_at HAS2 1.95 3.32 1.70 
226348_at --- 1.94 4.02 2.07 
201849_at BNIP3 1.88 2.69 1.43 
218507_at C7orf68 1.87 5.83 3.12 
228499_at PFKFB4 1.87 3.13 1.67 
228483_s_at TAF9B 1.82 4.91 2.70 
206693_at IL7 0.49 0.31 0.63 
225571_at LIFR 0.49 0.53 1.08 
210662_at KYNU 0.45 0.35 0.78 
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Probe Set ID Gene Symbol 
U87 
20 %vs 0.3% O2 
Glio6 
3% vs 0.3% O2 
Glio6 FCS 
3 %vs  0.3% O2 
203438_at STC2 2.97 10.02 3.94 
226452_at PDK1 3.44 5.24 3.25 
202912_at ADM 2.73 4.88 2.93 
202934_at HK2 2.19 4.37 4.18 
202856_s_at SLC16A3 2.50 4.33 2.49 
228483_s_at TAF9B 4.91 3.94 3.44 
202887_s_at DDIT4 3.99 3.91 4.09 
236480_at --- 4.16 3.89 2.71 
235850_at WDR5B 4.77 3.86 4.15 
236915_at C4orf47 5.49 3.67 2.38 
219410_at TMEM45A 5.02 3.44 2.84 
210512_s_at VEGFA 1.80 3.20 2.25 
230710_at LOC100506211 3.76 2.99 2.31 
220942_x_at FAM162A 2.89 2.95 2.54 
201010_s_at TXNIP 2.77 2.88 3.46 
225342_at AK3L1 4.50 2.86 3.75 
232693_s_at 
FBXO16 /// 
ZNF395 5.40 2.68 3.06 
205199_at CA9 8.99 2.64 3.20 
227068_at PGK1 2.72 2.64 2.18 
221123_x_at ZNF395 5.05 2.62 3.08 
201849_at BNIP3 2.69 2.56 2.29 
201250_s_at SLC2A1 5.69 2.35 2.70 
200632_s_at NDRG1 4.62 2.20 1.96 
202497_x_at SLC2A3 1.92 2.19 2.01 
232451_at --- 4.39 2.15 2.42 
223046_at EGLN1 2.44 2.08 1.95 
203282_at GBE1 1.98 2.02 1.81 
201313_at ENO2 2.35 1.99 2.29 
221479_s_at BNIP3L 2.12 1.97 1.91 
236180_at --- 3.87 1.96 2.50 
203710_at ITPR1 2.29 1.93 1.96 
225750_at ERO1L 2.61 1.84 1.92 
 
Table II 
